Nyxoah S.A. (NYXH) has announced the commercial launch of its Genio system in the Middle East, with the first successful implant performed at Saudi German Hospital in Dubai, UAE.
Genio is a groundbreaking, clinically proven therapy for Obstructive Sleep Apnea or OSA patients who cannot tolerate CPAP.
The launch of Genio marks a historic milestone as the first neurostimulation therapy for OSA in the region, offering new hope to OSA patients in the Middle East.
Under this expansion, Nyxoah aims to increase access to the innovative Genio system and transform the treatment landscape for OSA patients worldwide.
Olivier Taelman, CEO of Nyxoah, commented, "The commercial launch of Genio in the UAE marks an historic milestone as the first-ever neurostimulation therapy for Obstructive Sleep Apnea in the region. We are proud to bring this groundbreaking, patient-centric solution to the Middle East, offering new hope to patients who cannot tolerate CPAP."
Currently, NYXH is trading at $10.52 up by 0.38%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.